Skip to search formSkip to main contentSkip to account menu

Preveon

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1999
1999
  • J. James
  • AIDS treatment news
  • 1999
  • Corpus ID: 26402939
The FDA's Antiviral Drugs Advisory Committee voted against approval of adefovir dipivoxil (Preveon) for treating HIV. Although… 
Review
1999
Review
1999
  • A. Elwell
  • Positive Directions news : a support and…
  • 1999
  • Corpus ID: 6785225
Long-term management of HIV shows that combination therapy can achieve viral loads of under 50 copies, sustainable for 3 years… 
1999
1999
Updates are provided for new anti-HIV drugs currently in development. ABT-378, Tipranavir, and DMP-450 are among the new… 
1999
1999
  • Research initiative, treatment action : RITA
  • 1999
  • Corpus ID: 12336077
Data on Gilead's anti-HIV drug, adefovir dipivoxil (Preveon), were presented at the 12th International Conference on Antiviral… 
1998
1998
  • L. Highleyman
  • BETA : bulletin of experimental treatments for…
  • 1998
  • Corpus ID: 27581555
The trial program for adefovir dipivoxil (preveon), an anti-HIV drug, has been expanded to include individuals whose current… 
1998
1998
  • R. Baker
  • BETA : bulletin of experimental treatments for…
  • 1998
  • Corpus ID: 808743
Gilead Sciences, makers of adefovir dipivoxil (preveon), has observed varying levels of kidney-related abnormalities in… 
1998
1998
  • Positively aware : the monthly journal of the…
  • 1998
  • Corpus ID: 31840729
1998
1998
  • J. James
  • AIDS treatment news
  • 1998
  • Corpus ID: 39815207
Gilead Sciences has seen beneficial results from two trials of adefovir dipivoxil (Preveon) in the treatment of HIV. An… 
1998
1998
  • J. James
  • AIDS treatment news
  • 1998
  • Corpus ID: 370525
Gilead Sciences is removing the CD-4 and viral load requirements for people to enter its expanded access program for adefovir… 
1997
1997
  • N. Aronson
  • Notes from the underground
  • 1997
  • Corpus ID: 8241041
DuPont Merck opened an expanded access program for Sustiva (DMP 266). The program is open to AIDS patients with T-cell counts…